Evidence map›Paper›PMID 35258806›Full record

GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).

María Martínez-García, Sonia Servitja Tormo, Noelia Vilariño Quintela, Ana Arance Fernández, Alfonso Berrocal Jaime, Blanca Cantos Sánchez de Ibargüen, Sonia Del Barco Berrón, Rosario García Campelo, Regina Gironés Sarrió, Juan Manuel Sepúlveda-Sánchez

Open access · hybridAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. SEOM clinical guidelines (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

María Martínez-GarcíaMedical Oncology Department, Hospital del Mar, Barcelona, Spain. MariaMartinezGarcia@parcdesalutmar.cat.ORCID http://orcid.org/0000-0001-5891-3935
Sonia Servitja TormoMedical Oncology Department, Hospital del Mar, Barcelona, Spain.
Noelia Vilariño QuintelaMedical Oncology Department, Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Ana Arance FernándezMedical Oncology Department, Hospital Clínic, Barcelona, Spain.
Alfonso Berrocal JaimeMedical Oncology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
Blanca Cantos Sánchez de IbargüenMedical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
Sonia Del Barco BerrónMedical Oncology Department, Hospital Universitari Dr. Josep Trueta, ICO, Girona, Spain.
Rosario García CampeloMedical Oncology Department, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain.
Regina Gironés SarrióMedical Oncology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
Juan Manuel Sepúlveda-SánchezMedical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.
Hospital Del Mar · ESComplexo Hospitalario Universitario A Coruña · ESHospital Clínic de Barcelona · ESHospital General Universitario De Valencia · ESHospital Universitari de Girona Doctor Josep Trueta · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario 12 De Octubre · ESHospital Universitario Puerta de Hierro Majadahonda · ESInstitut Català d'Oncologia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood-brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.

Indexed as

Brain NeoplasmsCentral Nervous System NeoplasmsLung NeoplasmsMelanomaNeoplasms, Second PrimaryBrainCentral Nervous SystemHumansBlood–brain barrierBrain metastasisGuidelinesImmunotherapyTargeted therapies

Identifiers

PMID35258806
PMCPMC8986739
OpenAlexW4220705652

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.